CIS-DIAMMINEDICHLOROPLATINUM II

Grade III Glioma

Oliver JonasSmall moleculeEarly Phase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 95/ 100

Competitive context

6 Active assets in the Grade III Glioma cohort.

Asset / Sponsor	Phase	Rating
Nivolumab Sabine Mueller, MD, PhD	Phase 1	CC
Carboplatin Oliver Jonas	Early Phase 1	C
Cyclophosphamide Oliver Jonas	Early Phase 1	C
ETOPOSIDE Oliver Jonas	Early Phase 1	C
Ifosfamide Oliver Jonas	Early Phase 1	C
Inno-206 Oliver Jonas	Early Phase 1	C

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant

BBB

Indicative ·

78 / 100

primary peritoneal carcinomaDormant

BBB

Indicative ·

77 / 100

adenocarcinomaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.